Rheumatoid Arthritis

Tofacitinib citrate (Xeljanz) is an extended-release tablet for patients with moderate-to-severe rheumatoid arthritis.

Strong evidence suggests increased risk for respiratory, cardiovascular, and overall mortality for patients with RA.

The most commonly used biologic drugs to treat RA include etanercept, adalimumab, infliximab, and abatacept

Research seeks to to prevent the onset of an aggressive form of rheumatoid arthritis

RA patients who do yoga demonstrate benefits in health related quality of life measures.

Complications from conditions such as rheumatoid arthritis and lupus may cause cardiovascular problems.

Baricitinib is the only once-daily oral selective JAK1 and JAK2 inhibitor for the treatment of RA.

Baricitinib is the only once-daily oral selective JAK1 and JAK2 inhibitor for the treatment of RA.

High-intensity interval training found to increase ’ maximum oxygen uptake and improve the heart recovery rate in RA patients.

Being overweight or obese associated with a decreased risk of subsequent RA diagnosis.

Combination of diclofenac with chemotherapy and radiation may greatly improve treatment of cancer patients.

Sarilumab is a human monoclonal antibody that targets the IL-6 receptor.

Research finds self-management of RA and patient exercise can reduce pain and disability.

Research suggests psychosocial comorbidities and elevated risk of atherosclerosis in RA patients.

This study applied a validated algorithm to estimate the effectiveness and costs of the index biologic used by 4696 US veterans with rheumatoid arthritis.

Test diagnoses RA with better accuracy by detecting synthetic citrullinated peptides.

Excess production of tumor necrosis factor causes both RA and the onset of heart valve disease.

Submission bolstered by trials evaluating biosimilar candidate in moderate-to-severe plaque psoriasis and rheumatoid arthritis.

Research finds patients are not staying on methotrexate long enough before switching to more costly biologic drugs.

Tofacitinib effective in the treatment of moderate to severe atopic dermatitis.

Positive mood throughout daily life linked to less pain and fewer RA-related restrictions.

Treatment with sarilumab improves RA signs, symptoms, and physical function.

Baricitinib improved disease activity in patients not responding to conventional or biologic DMARDs.

Biosimilar may offer patients with RA drug cost relief in the near future.

Experimental DMARD may be clinically beneficial for active rheumatoid arthritis treatment.

Risk of death in patients with cardiovascular and respiratory conditions amplified in female patients with rheumatoid arthritis.

Strategy reduces cost without compromising RA symptom control.